Answer each question to find trials that best match your clinical situation. You can leave questions blank if you do not know the answer.
This search will output a list of trials for which you may be eligible based on the criteria you enter.
Matching Trials
For more detailed information please click on the clinical trial number and you will be taken to the clinicaltrials.gov website.
For a key to the icons and text used in the Results column, please click here.
To learn more about our trial annotation process, results assignments, and the criteria used to highlight drugs with promising results, please click here.
| NCT05329545 | III | High grade serous NaPi2b+ ovarian cancer with platinum-sensitive recurrence and CR, PR or SD in most recent platinum-based therapy | A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Upifitamab Rilsodotin (XMT-1536) as Post-Platinum Maintenance Therapy for Participants With Recurrent, Platinum-Sensitive, Ovarian Cancer (UP-NEXT) | MA | View Drugs | View Results |
| Placebo | | | | | Upifitamab rilsodotin | XMT-1536, UpRi | ADC: anti-NaPi2b + microtubule destabilizer (auristatin F-HPA) | Clinical Trials |
|
|
| NCT04377087 | II | Platinum sensitive ovarian cancer with response to most recent Pt-based therapy (maintenance) | Phase IIA Trial of Delayed Initiation of Olaparib Maintenance Therapy in Platinum Sensitive Recurrent Ovarian Cancer | PA | View Drugs | |
|
|
| NCT04804007 | II | Germ cell tumors after treatment with high-dose chemotherapy (HDCT) and peripheral-blood stem-cell transplant (PBSCT) (maintenance) | Randomized Phase 2 Trial of Maintenance Oral Etoposide or Observation Following High-dose Chemotherapy for Relapsed Metastatic Germ-Cell Tumor | IN | View Drugs | |
| Etoposide | VePesid, Toposar, Lastet, epipodophyllotoxin | Topoisomerase II inhibitor | |
|
|
